chevron_leftBack
As of 5 June 2026, Gelteq Ltd. has a market cap of $6.96M USD, ranking #43079 globally and #1461 in Australia.
It ranks #3811 in the Healthcare sector, and #1230 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$6.96MUSD
Enterprise Value
$9.72MUSD
Revenue (TTM)
$270.85KUSD
EBITDA (TTM)
-$2.52MUSD
Net Income (TTM)
-$4.36MUSD
PS Ratio
26.5
PB Ratio
0.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Nathan Givoni
open_in_new
Employees
8
Founded
2018
IPO
29 Oct 2024
Website
gelteq.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3% | -10% | -6.9% | -34% | -44% | -71% |
News
Loading...
GELS Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GELS
Gelteq Ltd
ISIN: AU0000218109
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.6499 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Gelteq Ltd.
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
ASX: SIG
|
$22.82B
328K%
31.98B AUD
|
52.3
|
|
ASX: PYC
|
$926.22M
13K%
1.3B AUD
|
-
|
|
ASX: RAC
|
$346.24M
5K%
485.18M AUD
|
-
|
|
ASX: CUV
|
$335.4M
5K%
469.99M AUD
|
14.5
|
|
ASX: SPL
|
$216.39M
3K%
303.23M AUD
|
-
|
|
ASX: MYX
|
$166.4M
2K%
233.18M AUD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
11M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
8M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
5M%
|
97.4
|
|
SIX: RO
|
$324.68B
5M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.43B
4M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$277.35B
4M%
218.9B CHF
|
20.5
|
chevron_leftBack